The 200-Year Timeline on Botulinum Toxin: From Biologic Poison to Wonder Drug

被引:1
|
作者
Dong, Joanna [1 ]
Helveston, Eugene M. [1 ]
Hanke, C. William [1 ]
机构
[1] Ascens St Vincent Hosp, Indianapolis, IN 46260 USA
关键词
D O I
10.36849/JDD.7288
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The history of botulinum toxin dates back to the late 1700s, when food preparation, storage, and later canning practices led to outbreaks of botulism across Europe and the United States. It is from these initial incidents that the remarkable discovery of botulinum toxin was eventually made, sparking over 200 years of further scientific inquiry and medical innovation. To date, 6 botulinum toxin products have been commercialized in North America with numerous indications across the specialties of ophthalmology, neurology, urology, dermatology, plastic surgery, and otolaryngology. This article traces the key moments and important players in the remarkable journey of this biologic poison and wonder drug.
引用
收藏
页码:1357 / 1359
页数:3
相关论文
共 42 条
  • [31] Increasing heavy metals in the background atmosphere of central North China since the 1980s: Evidence from a 200-year lake sediment record
    Wan, Dejun
    Song, Lei
    Yang, Jinsong
    Jin, Zhangdong
    Zhan, Changlin
    Mao, Xin
    Liu, Dongwei
    Shao, Yue
    ATMOSPHERIC ENVIRONMENT, 2016, 138 : 183 - 190
  • [33] The zurich experiences including 6 year results of 200 cases treated with low-dose (100 U) Botulinum-A toxin injections into the detrusor muscle for overactive bladder refractory to anticholinergics
    Schmid, Daniel M.
    Roy-Guggenbuehl, Sharmistha G.
    Werner, Matthias
    Perucchini, Daniele
    Sulser, Tullio
    Schurch, Brigitte
    JOURNAL OF UROLOGY, 2008, 179 (04): : 566 - 566
  • [34] Ventricular Dysrhythmias Associated with Poisoning and Drug Overdose: A 10-Year Review of Statewide Poison Control Center Data from California
    Suad A. Al-Abri
    Claire Woodburn
    Kent R. Olson
    Thomas E. Kearney
    American Journal of Cardiovascular Drugs, 2015, 15 : 43 - 50
  • [35] Ventricular Dysrhythmias Associated with Poisoning and Drug Overdose: A 10-Year Review of Statewide Poison Control Center Data from California
    Al-Abri, Suad A.
    Woodburn, Claire
    Olson, Kent R.
    Kearney, Thomas E.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2015, 15 (01) : 43 - 50
  • [36] Earthquake, floods and changing land use history: A 200-year overview of environmental changes in Selenga River basin as indicated by n-alkanes and related proxies in sediments from shallow lakes
    Martins, Cesar C.
    Adams, Jennifer K.
    Yang, Handong
    Shchetnikov, Alexander A.
    Di Domenico, Maikon
    Rose, Neil L.
    Mackay, Anson W.
    SCIENCE OF THE TOTAL ENVIRONMENT, 2023, 873
  • [37] Predictors of Adherence on Ambulatory Botulinum Neurotoxin Injections for Dystonia, Spasticity, and Hemifacial Spasms: A Three-Year Timeline From March 2019 to February 2022, Before and During the COVID-19 Pandemic
    Doquenia, Maria Leila
    Lucban, Jan Pierre
    Tanglao, Michelle
    Rosales, Raymond
    TOXICON, 2024, 237 : 23 - 23
  • [38] Botulinum toxin A improves bladder function without drug-related adverse events in patients with neurogenic detrusor overactivity:: results from a randomised, double-blind, placebo-controlled study
    Schurch, B
    de Sèze, M
    Denys, P
    Chartier-Kastler, E
    Haab, F
    Everaert, K
    Plante, P
    Perrouin-Verbe, B
    Fraczek, S
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S81 - S82
  • [39] Patterns in the Sequential Treatment of Patients With Rheumatoid Arthritis Starting a Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug: 10-Year Experience From a US-Based Registry
    Matsson, Anton
    Solomon, Daniel H.
    Crabtree, Margaux M.
    Harrison, Ryan W.
    Litman, Heather J.
    Johansson, Fredrik D.
    ACR OPEN RHEUMATOLOGY, 2024, 6 (01) : 5 - 13
  • [40] Primary 1-Year Data of Ixekizumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naive Patients with Radiographic Axial Spondyloarthritis Including Data in Patients Rerandomized from Adalimumab to Ixekizumab
    Wei, Cheng-Chung
    Gensler, Lianne
    Walsh, Jessica
    Landewe, Robert B. M.
    Tomita, Tetsuya
    Zhao, Fangyi
    Gallo, Gaia
    Carlier, Hilde
    Dougados, Maxime
    ARTHRITIS & RHEUMATOLOGY, 2019, 71